Predictive Value of PAI-1 Plasma Activity and Thallium Perfusion Imaging for Restenosis after Percutaneous Transluminal Angioplasty in Clinically Asymptomatic Patients

Summary

Background. The main long-term complication of percutaneous transluminal coronary angioplasty (PTCA) is restenosis that occurs in 30-50 percent of all primary successful cases. The purpose of this study was to evaluate the predictive value of changes in plasminogen activator inhibitor-1 (PAI-1) activity and of thallium dipyridamole perfusion imaging performed 3 months after successful angioplasty. All patients were asymptomatic at evaluation. The results of these two noninvasive tests were compared with the angiographic outcome after 6 months.

Methods and Patients. Twenty-five patients were included in this prospective study. All patients had single vessel disease, successful angioplasty and were free of clinical symptoms 3 months after angioplasty that would suggest late restenosis. In 12/25 patients (48%) angiographic restenosis (percent diameter stenosis >50%) was determined by follow-up angiography 6 months after angioplasty. PAI-1 plasma activity was determined by a functional titration assay and increase or decrease of PAI-1 plasma activity was evaluated between values obtained before and 3 months after angioplasty. In 7/25 (28%) patients PAI-1 plasma activity increased to more than 90% of pre-angioplasty values. This increase correlated with angiographic restenosis evaluated 6 months after angioplasty (sensitivity 42%, specificity 85%, positive predictive value 71%, and negative predictive value 61%). Tl-201-perfusion imaging was performed 3 months after angioplasty. This test was indicative for subsequent restenosis in 5/25 patients (sensitivity 33%, specificity 100%, positive predictive value 62%, and negative predictive value 100%). In 10/25 (40%) patients at least one of the two non-invasive tests performed 3 months after angioplasty predicted angiographic restenosis at 6 months; the combined use of PAI-1 and Tl-201-perfusion imaging resulted in increased sensitivity (67%) and high specificity (85%).

Conclusion. The results of this study indicate that an increase of PAI-1 plasma activity may improve the predictive value for restenosis of Tl-201-scintigraphy performed 3 months after angioplasty even in asymptomatic patients.

• References

• 1 Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-8.
• 2 Gottsauner-Wolf M, Moliterno DJ, Lincoff AM, Topol EJ. Restenosis – an open file. Clin Cardiol 1996; 19: 347-56.
• 3 Bengtson JR, Mark DB, Honan MB, Rendall DS, Hinohara T, Stack RS, Hlatky MA, Califf RM, Lee KL, Pryor DB. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. Am J Cardiol 1990; 65: 28-34.
• 4 Hillegas WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In Textbook of Interventional Cardiology. Topol EJ. ed. WB Saunders; Philadelphia: 1993. pp 415-35.
• 5 Holmes DRJ, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM, van Raden MJ, Mock MB. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53: 77C-81C.
• 6 Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616-23.
• 7 Huber K, Jörg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemostas 1992; 67: 209-13.
• 8 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
• 9 Faxon DP, Sanborn TA, Haudenschild CC, Ryan TJ. Effect of antiplatelet therapy on restenosis after experimental angioplasty. Am J Cardiol 1984; 53: 72C-6C.
• 10 Frebelius S, Hedin U, Swedenborg J. Thrombogenicity of the injured vessel wall-role of antithrombin and heparin. Thromb Haemostas 1994; 71: 147-53.
• 11 Salomaa V, Stinson V, Kark JD, Folson AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation 1995; 91: 284-90.
• 12 Paramo JA, Colucci M, Colleri D. Plasminogen activator inhibitor in blood of patients with coronary artery disease. Br Med J 1985; 295: 573-4.
• 13 Hamsten A, Wiman B, De Faire U, Blombäck M. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
• 14 Huber K, Resch I, Rosc D, Schuster E, Glogar D, Binder BR. Circadian variation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemostas 1988; 60: 372-6.
• 15 Huber K, Resch I, Stefenelli T, Lang I, Probst P, Kaindl F, Binder BR. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 1990; 63: 336-9.
• 16 Marie P, Danchin N, Karcher G, Grentzinger A, Juilliere Y, Olivier P, Buffet P, Anconina J, Beurrier D, Cherrier F, Bertrand A. Usefulness of exercise SPECT-thallium to detect asymptomatic restenosis in patients who had angina before coronary angioplasty. Am Heart J 1993; 126: 571-7.
• 17 Hecht HS, Shaw RE, Chin HL, Ryan C, Stertzer SH, Myler RK. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991; 17: 670-7.
• 18 Wijns W, Serruys PW, Reiber JHC, de Feyter PJ, van den Brand M, Simoons ML, Hugenholtz PG. Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. Am J Cardiol 1985; 55: 357-61.
• 19 Scholl JM, Chaitman BR, David PR, Dupras G, Brevers G, Val PG, Crepeau J, Lesperance J, Bourassa MG. Exercise electrocardiography and myocardial scintigraphy in the serial evaluation of the results of percutaneous transluminal coronary angioplasty. Circulation 1982; 66: 380-90.
• 20 Ishiwata S, Nakanishi S, Nishiyama S, Seki A. Prevention of restenosis by bezafibrate after successful coronary angioplasty. Coron Artery Dis 1995; 6: 883-9.
• 21 Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
• 22 Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994; 330: 981-93.
• 23 Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-6.
• 24 Huber K, Beckmann R, Lang I, Schuster E, Binder BR. Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity. Fibrinolysis 1989; 3: 41-3.
• 25 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in plasma. Thromb Haemost 1984; 51: 392-5.
• 26 Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr 50,000 antiactivator. J Lab Clin Med 1985; 105: 718-24.
• 27 Gould KL, Lipscomb K, Hamilton GW. Physiologic basis of assessing critical coronary stenosis. Am J Cardiol 1974; 33: 87-94.
• 28 Serruys P, Breeman A. Coronary angioplasty – long-term follow-up results and detection of restenosis: guidelines for aviation cardiology: a European view. Eur Heart J 1992; 13: 76-88.
• 29 Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JHC, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 1988; 77: 361-71.
• 30 The BARI investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96: 1761-9.
• 31 Rupprecht HJ, Brennecke R, Bernhard G, Erbel R, Pop T, Meyer J. Analysis of risk factors for restenosis after PTCA. Cathet Cardiovasc Diagn 1990; 19: 151-9.
• 32 Hirshfeld JW, Schwartz JS, Jugo R, MacDonald RG, Goldberg S, Savage MP, Bass TA, Vetrovec G, Cowley M, Taussig AS, Whitworth HB, Mar-golis JR, Hill JA, Pepine CJ. Investigators TM-H. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991; 18: 647-56.
• 33 Maresta A, Balducelli M, Cantini L, Casari A, Chioin R, Fabbri M, Fontanelli A, Preti PA, Repetto S, de Dervi S, Varani E. for the STARC Investigators. Trapidil (Triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Circulation 1994; 90: 2710-5.
• 34 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tscheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Westen M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
• 35 Lins M, Zurborn KH, Dau O, Nagel E, Muurling S, Herrmann G, Simon R. Coagulation activation in patients undergoing directional coronary atherectomy. Thromb Res 1997; 86: 433-41.
• 36 Ali MN, Mazur W, Kleiman NS, Rodgers GP, Abukhalil JM, French BA, Raizner AE. Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine. Coron Artery Dis 1996; 7: 851-61.
• 37 Barry WL, Gimple LW, Humphries JE, Powers ER, McCoy KW, Sanders JM, Owens GK, Sarembock IJ. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model: time course and effect of hirudin. Circulation 1996; 94: 88-93.
• 38 Cereck B, Yamashita M, Dimayuga P, Zhu J, Fishbein MC, Kaul S, Shah PK, Nilsson J, Regnstrom J. Nuclear factor-κ B activity and arterial response to balloon injury. Atherosclerosis 1997; 131: 59-66.
• 39 Manning AM, Bell FP, Rosenbloom CL, Chosay JG, Simmons CA, Northruop JL, Shebuski RJ, Dunn CJ, Anderson DC. NF-κ B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment. J Inflamm 1995; 45: 283-96.
• 40 Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-92.
• 41 Shi Y, Hutchinson H, Hall D, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 1993; 88: 1190-5.